<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sonnenblick, Amir</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Docetaxel Added to Anthracycline Regimens Benefits Patients with Highly Proliferative ER-Positive Breast Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Adding taxanes to an anthracycline-based chemotherapy regimen in the adjuvant setting has become a standard approach in the management of patients with breast cancer. However, long-term outcomes data are still lacking regarding the safety and efficacy of this approach. This article presents data from the 10-year final safety and efficacy analyses of the Intergroup Phase 3 BIG 2-98 trial [NCT00174655].</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>